Exploring the Long Term Safety, Tolerability and Clinical Effect of Laquinimod

Study Title
An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
Teva Identifier
LAQ/5063OL | LAQ/5063 | 2005-004334-41
ClinicalTrials.gov Identifier
NCT00745615
Study Status
Terminated
Trial Condition(s)
Relapsing Remitting Multiple Sclerosis
Interventions
Drug: Laquinimod | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 50 Years
Trial Duration
December 7, 2005 - July 23, 2017
Phase
Phase 2

Study Type

Interventional